CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Keywords:
Oncolytic viruses
Brain neoplasms
Note:
This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license
The performed work was supported through the Departamento de Salud
del Gobierno de Navarra (54/2018-APG); Predoctoral Fellowship from Gobierno
de Navarra (VL), Instituto de Salud Carlos III y Fondos Feder (PI19/01896 MMA,
PI19/01440 JGPL, PI18/00164 APG); AECC/ERA-Permed-GAL20732 (JGPL),
Amigos de la Universidad de Navarra (to MP); Fundación La Caixa/Caja Navarra
and Fundación ACS (APG and MA); Fundación ADEY (APG, MA), Fundación El sueño
de Vicky; Asociación Pablo Ugarte-Fuerza Julen (APG and MA); Comunidad de la
Guareña (JGPL, APG, MA) and Department of Defense (DOD) Team Science Award
under grant CA 160525 (MA, CG-M and JF). This project also received funding from
the European Research Council (ERC) under the European Union's Horizon 2020
Research and Innovation Program (817 884 ViroPedTher to MA).
Citation:
Puigdelloses-Vallcorba, M. (Montserrat); García-Moure, M. (Marc); Labiano-Almiñana, S. (Sara); et al. "CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models". Journal for Immunotherapy of Cancer. 9 (7), 2021, e002644
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.